 Hello everybody and welcome back to Investor Intel. I'm Peter Klossy back with Thomas Smink who I've known since I think 1998 Correct Today we're talking about hemostemics where Tom is the CEO Tom tell us about the technology within the company Sure. It's really a platform technology Peter. It comes from the patient's own blood What we do is we take a cup of blood from the patient's arm We fractionate out their stem cells from that cup of blood and then we culture them and change them from a raw stem cell Into an angiogenic cell precursor that's programmed to address Ischemia in the circulatory system of the body right and ischemia is common in diabetics, right? It's in it's common in diabetics. It's common in Individuals who suffer from heart disease such as angina or ischemic cardiomyopathy. It's common in individuals who suffer from COPD a lung condition it's It's common in wound care in the right in in bed sores and In wounds that won't heal in individuals who have lost circulation It's also common in you have a back scratch that won't go away. That's that's peripheral neuropathy It's common. I thought that was I thought that was a family member It could be but it but that's a that's a you know, that's it another form of Reduction and circulation that results in and itchy So hemostemics has actual sales. This isn't a theory. This is a proven success We have treated more than 500 individuals on a compassionate basis That was mostly in the time period when I ran the company as a private company from 2006 to 2011 the end of 2011 Now we're in clinical trials and the previous management team Stopped the revenue side of the business to focus just on clinical trials I'm going I'm ramping the I'm ramping the revenue side of the business backup. So you mentioned it's a platform technology What else can you use it for? So ACP is the first Derivation that we we derive from the patient's own stem cells the second one that we patented is NCP neuronal cell precursors And this is a a cell that can be used to treat stroke. It can be used to treat Diseases of nerve that have nerve damage. So Degeneration of nerves in the optic nerve in preparation for this I took a look at the stock market your stock is up today And it's had it looks like it's had a general trend upwards So congratulations to you for rejoining the company and appearing to fix what had been wrong Can we check in with you at the quarter? Yes, please. That'd be fantastic. I hope you have a great safe day I'm Peter Clausi signing off from investor Intel Thomas Mink from Hemostamix trading as HEM on the venture exchange